PF-Atlas › Clinical Trials › NCT07482917

Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

Standard ILD Diagnostic Pathway · Not specified

Registry ID
NCT07482917
Phase
Not specified
Status
Recruiting
Drug / intervention
Standard ILD Diagnostic Pathway
Sponsor
Hospital de Granollers
Start
2026-03-09
Enrollment
92
Locations
1

About this trial

The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe. All eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-wor

View NCT07482917 on ClinicalTrials.gov →

Medical disclaimer. This page summarizes public trial data for NCT07482917 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.